Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers identify molecule that causes destructive lung inflammation in cystic fibrosis patients

08.11.2006
Discovery offers scientists a target for developing new treatments that could improve quality of life

Scientists at Children's Hospital of Pittsburgh of UPMC have identified a protein that is critical to the development of inflammation during lung infection in patients with cystic fibrosis (CF). The identification of this protein, called interleukin-23 (IL-23), is an important finding that gives researchers a specific target for developing new therapies.

In June 2005, Children's and University of Pittsburgh researchers led by Children's pulmonologist and immunologist Jay K. Kolls, MD, reported that IL-23 and another cytokine, interleukin-17, are elevated in CF patients with chronic lung infections. The latest research by Dr. Kolls and Children's pulmonologist Patricia Dubin, MD, pinpoints IL-23 as the crucial mediator to this inflammatory response. Results of this study are now published online in the American Journal of Physiology-Lung Cellular and Molecular Physiology.

Many patients with CF develop chronic lung infections from a strain of bacteria known as Pseudomonas aeruginosa. During chronic infection, the inflammatory response is never "shut off", and the continuous inflammation, mediated by IL-23 and other cytokines, may eventually lead to lung damage.

... more about:
»IL-23 »cystic »fibrosis »inflammation »inflammatory

"Understanding the role IL-23 plays in the inflammatory pathway of CF patients is a major step forward that could lead to the development of new therapies to block this inflammation," said Dr. Kolls, chief of the Division of Pulmonary Medicine, Allergy and Immunology at Children's and professor of Pediatrics and Immunology at the University of Pittsburgh School of Medicine. "For patients with chronic infections associated with CF, this eventually could mean a prolonged life span and an improved quality of life."

Examining IL-23's importance in the inflammation pathway is a "new and different" approach than that taken by other CF researchers, according to Dr. Dubin, an assistant professor of Pediatrics at the University of Pittsburgh School of Medicine. "Currently, the anti-inflammatory therapies that we have for CF patients, steroids and non-steroidal anti-inflammatory drugs, are non-specific and can cause debilitating side effects such as the exacerbation of diabetes and glucose intolerance, as well as bone loss. The identification of specific inflammatory mediators like IL-23 opens the door to developing targeted anti-inflammatory treatments which may have fewer side effects."

CF is an inherited disease characterized by an abnormality in the body's salt-, water- and mucus-making cells. It is chronic, progressive and life-shortening. About 30,000 people in the United States have CF and about 1,000 babies are born with it each year. The life expectancy of a child born with CF is 36.5 years. The Antonio J. and Janet Palumbo CF Center at Children's follows more than 430 patients.

Children with CF have an abnormality in the function of a cell protein called the cystic fibrosis transmembrane regulator. This affects the flow of water and certain salts in and out of the body's cells, leading to the production of abnormally thick mucus. The thickened mucus can affect many organs and body systems, including the sinuses and lungs, pancreas, liver, gallbladder, intestines, and reproductive and sweat glands. In the sinuses and lungs, this thickened mucus allows bacteria that would normally be cleared from the airways to multiply and cause chronic infection.

Marc Lukasiak | EurekAlert!
Further information:
http://www.chp.edu

Further reports about: IL-23 cystic fibrosis inflammation inflammatory

More articles from Life Sciences:

nachricht The birth of a new protein
20.10.2017 | University of Arizona

nachricht Building New Moss Factories
20.10.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>